Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center

Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major bleeding events. We aimed to review the incidence of effective hemostasis with andexanet alfa in a real-world environment. This retrospective cohort included patients hospitalized for a major bleed that result...

Full description

Bibliographic Details
Main Authors: Victoria M. Stevens PharmD, Toby Trujillo PharmD, FCCP, FAHA, BCPS-AQ Cardiology, Scott W. Mueller PharmD, BCCCP, FCCM, Robert MacLaren PharmD, FCCM, FCCP, Paul M. Reynolds PharmD, BCCCP, Tyree H. Kiser PharmD, FCCM, FCCP, BCPS
Format: Article
Language:English
Published: SAGE Publishing 2019-12-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/1076029619896619

Internet

https://doi.org/10.1177/1076029619896619

Similar Items